期刊
BIOMEDICINES
卷 11, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines11113035
关键词
Alzheimer's disease; antidiabetic drugs; neuroprotection; GLP-1 analogs; DPP-4 inhibitors; SGLT-2 inhibitors
This review comprehensively assesses the potential therapeutic applications of new-generation anti-diabetic drugs in the context of Alzheimer's disease, highlighting the well-documented correlation and shared mechanisms between diabetes and Alzheimer's disease.
Alzheimer's is a prevalent, progressive neurodegenerative disease marked by cognitive decline and memory loss. The disease's development involves various pathomechanisms, including amyloid-beta accumulation, neurofibrillary tangles, oxidative stress, inflammation, and mitochondrial dysfunction. Recent research suggests that antidiabetic drugs may enhance neuronal survival and cognitive function in diabetes. Given the well-documented correlation between diabetes and Alzheimer's disease and the potential shared mechanisms, this review aimed to comprehensively assess the potential of new-generation anti-diabetic drugs, such as GLP-1 analogs, SGLT-2 inhibitors, and DPP-4 inhibitors, as promising therapeutic approaches for Alzheimer's disease. This review aims to comprehensively assess the potential therapeutic applications of novel-generation antidiabetic drugs, including GLP-1 analogs, SGLT-2 inhibitors, and DPP-4 inhibitors, in the context of Alzheimer's disease. In our considered opinion, antidiabetic drugs offer a promising avenue for groundbreaking developments and have the potential to revolutionize the landscape of Alzheimer's disease treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据